PharmaLogic Bolsters Radiopharmaceutical Expertise with Agilera Acquisition

PharmaLogic Expands Reach with Agilera Acquisition

In a strategic move aimed at enhancing its capabilities in the burgeoning field of radiopharmaceuticals, PharmaLogic Holdings Corp. has announced its decision to acquire a majority stake in Agilera Pharma AS. The acquisition, heralded as a transformative step towards establishing PharmaLogic as a leading global contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical therapies, underscores the company's commitment to innovation and expansion within the industry.

Based in Boca Raton, Florida, PharmaLogic has built a reputation as a premier CDMO with a focus on novel diagnostic imaging and therapeutic radiopharmaceuticals. The company’s latest acquisition of Agilera, a well-respected player in the field based in Oslo, Norway, marks a significant leap forward. Agilera has been a trusted entity for major pharmaceutical companies for over a decade, delivering over 600,000 therapeutic doses across more than 40 countries, thus solidifying its position in the radiopharmaceutical CDMO sector.

In a statement, Etienne Montagut, President of PharmaLogic, expressed enthusiasm over the acquisition, stating, "Combining our expertise with Agilera's industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale." This collaboration is expected to ultimately enhance patient access to critical treatments in the radiopharmaceutical domain.

Agilera, recognized as one of only two CDMOs globally manufacturing radiopharmaceutical therapeutics, will significantly bolster PharmaLogic's existing capabilities. This partnership is positioned to create synergies that enhance infrastructure and production capabilities, meeting the increasing global demand for radiopharmaceuticals. Under the agreement, PharmaLogic plans to invest heavily in Agilera's CDMO capabilities, further expanding their operational footprint to ensure they can meet burgeoning market requirements.

Nils Morten Huseby, CEO of the Institute for Energy Technology (IFE), from which Agilera is being acquired, remarked on the significance of this sale, describing it as a landmark achievement for IFE's commercialization efforts. The partnership between PharmaLogic and Agilera is seen as a pathway to rapid growth, increased operational capacity, and expanded market reach, particularly in Europe.

Erik Flatmark, CEO of Agilera, conveyed confidence in the new partnership, highlighting that the experience and expertise of Agilera's workforce have been critical assets. He illustrated that with PharmaLogic on board, Agilera could further bolster its production capabilities and expedite adaptation to new market opportunities. Moreover, Flatmark noted that enhancing distribution networks will be essential for both companies to cater effectively to customers across Europe, the United States, and globally.

As part of the acquisition process, the closing of the transaction will be subject to typical conditions such as regulatory approvals and license transfers, with an anticipated completion date set for June 2025.

PharmaLogic's strategic acquisition of Agilera positions the company to become a dominant player in the global radiopharmaceuticals market. This move not only enhances its manufacturing capabilities but also amplifies its reach in addressing the healthcare needs of patients worldwide. With its extensive experience in drug development and an established network of radiopharmacies, PharmaLogic is poised to lead advancements in radiopharmaceutical technology, ensuring the delivery of innovative treatment solutions to patients across diverse healthcare landscapes.

In conclusion, this acquisition is expected to set the stage for a new era in radiopharmaceutical therapeutics, with PharmaLogic and Agilera working in tandem to navigate the complexities of this high-growth field, thus significantly impacting patient care and treatment outcomes globally.

For more information, visit radiopharmacy.com and follow PharmaLogic on LinkedIn.